Advertisement
GILD vs GSK
Which Stock Would AI Choose? Gilead Sciences (GILD) vs. GSK plc (GSK) Stock Comparison
Key Takeaways
- GILD has delivered stronger year-to-date (YTD) performance at 7.87% compared to GSK's 6.09%, reflecting robust momentum in recent market activity.
- GSK offers a higher dividend yield of 3.49% versus GILD's 2.49%, appealing to income-oriented investors.
- Analyst price targets suggest greater upside potential for GILD at an average of $158.36 (about 20% from current levels) compared to GSK's $57.65 (around 12%).
- Both stocks exhibit low volatility with betas around 0.33-0.35, providing stability amid market fluctuations.
- GILD trades at a higher price-to-earnings (P/E) ratio of 19.42 versus GSK's 13.44, indicating expectations of stronger growth.
Introduction
Healthcare giants GILD and GSK offer defensive exposure to the pharmaceutical and biotechnology sectors, making them attractive for investors seeking stability with growth potential. This stock comparison evaluates their recent performance, business drivers, and market positioning in the current environment. Traders focused on relative performance, dividend income, or pipeline catalysts will find value in understanding contrasts between GILD's antiviral and oncology focus and GSK's vaccine and specialty medicine portfolio. With both exhibiting low betas, they suit portfolios balancing risk and reward amid volatility.
GILD Overview and Recent Performance
Gilead Sciences (GILD), a leading biopharmaceutical company, specializes in treatments for HIV/AIDS, viral hepatitis, oncology, and inflammation. Key products include Biktarvy and other HIV therapies, Epclusa for hepatitis C, and cell therapies like Yescarta and Tecartus. In recent weeks, GILD stock has shown resilience, outperforming the broader market on certain sessions with gains around 1.55%, trading near $131.65 with a market cap of $163 billion. Sentiment has been bolstered by FDA priority review for a new HIV treatment, pipeline acquisitions, and a Citigroup Buy rating with a raised price target to $165, driving YTD gains of 7.87% despite occasional pullbacks.
GSK Overview and Recent Performance
GSK plc (GSK) is a global biopharma firm emphasizing vaccines, specialty medicines in HIV, oncology, and respiratory diseases, alongside general medicines. Flagship products feature Shingrix for shingles, Arexvy for RSV, and therapies for COPD and asthma. Recent market activity has seen GSK trading around $51.61 with a $103 billion market cap, posting YTD returns of 6.09% amid a strong Q1 driven by specialty medicines growth. Positive factors include robust sales from Shingrix, reaffirmed outlook, and collaborations like mRNA vaccines, though some sessions reflected minor declines; a dividend of $0.34 was announced.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 total bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots excel in current volatile conditions, featuring impressive stats such as annualized returns from 23.53% to 163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70. Strategies vary by timeframe (e.g., 5min to 60min) and style, including trend trading and dip-buying focused on sectors like semiconductors and data centers. Ideal for copy trading, they highlight bots best suited to recent market dynamics. Explore Trending AI Robots to identify tools matching your approach.
Head-to-Head Comparison
GILD and GSK both anchor in healthcare but diverge in focus: GILD leans biotech with high-margin antivirals and oncology cell therapies, while GSK balances vaccines and broader specialty/general medicines for diversified revenue. Growth drivers contrast with GILD's HIV/oncology pipeline versus GSK's Shingrix/RSV momentum. Recent momentum favors GILD with superior YTD gains and market outperformance, though GSK edges in dividend yield. Risk profiles align closely with low betas (0.33 vs. 0.35), but GILD's higher P/E signals growth premium amid similar return on equity around 40%. Market sentiment tilts toward GILD via elevated analyst targets.
Tickeron AI Verdict
Tickeron's AI models currently lean toward GILD with higher probability due to consistent trend strength, superior YTD relative performance, and greater analyst-upside potential from pipeline catalysts like HIV advancements. While GSK provides solid income stability, GILD's positioning suggests stronger near-term momentum in the biotech space, though both remain viable based on risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and GSK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).
- GILD’s FA Score: 3 green, 2 red.
- GSK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 4 TA indicator(s) are bullish while GSK’s TA Score has 3 bullish TA indicator(s).
- GILD’s TA Score: 4 bullish, 5 bearish.
- GSK’s TA Score: 3 bullish, 5 bearish.
Price Growth
GILD (@Pharmaceuticals: Major) experienced а -1.03% price change this week, while GSK (@Pharmaceuticals: Major) price change was -4.14% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
GILD is expected to report earnings on Jul 30, 2026.
GSK is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GILD | GSK | GILD / GSK | |
| Capitalization | 154B | 103B | 150% |
| EBITDA | 14.5B | 10.1B | 144% |
| Gain YTD | 2.070 | 5.106 | 41% |
| P/E Ratio | 16.84 | 13.28 | 127% |
| Revenue | 29.7B | 32.8B | 91% |
| Total Cash | N/A | 3.44B | - |
| Total Debt | 22.2B | 19.1B | 116% |
GILD | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 23 | 41 | |
SMR RATING 1..100 | 22 | 27 | |
PRICE GROWTH RATING 1..100 | 58 | 51 | |
P/E GROWTH RATING 1..100 | 78 | 80 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (8) in the Biotechnology industry is in the same range as GSK (15) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.
GILD's Profit vs Risk Rating (23) in the Biotechnology industry is in the same range as GSK (41) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.
GILD's SMR Rating (22) in the Biotechnology industry is in the same range as GSK (27) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.
GSK's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as GILD (58) in the Biotechnology industry. This means that GSK’s stock grew similarly to GILD’s over the last 12 months.
GILD's P/E Growth Rating (78) in the Biotechnology industry is in the same range as GSK (80) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GSK’s over the last 12 months.
| GILD | GSK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 56% | N/A |
| Stochastic ODDS (%) | 3 days ago 54% | 3 days ago 46% |
| Momentum ODDS (%) | 3 days ago 45% | 3 days ago 43% |
| MACD ODDS (%) | 3 days ago 50% | 3 days ago 56% |
| TrendWeek ODDS (%) | 3 days ago 46% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 50% | 3 days ago 58% |
| Advances ODDS (%) | 17 days ago 61% | 9 days ago 61% |
| Declines ODDS (%) | 3 days ago 48% | 3 days ago 54% |
| BollingerBands ODDS (%) | 3 days ago 59% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 59% | 3 days ago 39% |
Advertisement
GILD and
Correlation & Price change
A.I.dvisor indicates that over the last year, GILD has been loosely correlated with NVS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To GILD | 1D Price Change % | ||
|---|---|---|---|---|
| GILD | 100% | -1.35% | ||
| NVS - GILD | 48% Loosely correlated | -2.52% | ||
| AMGN - GILD | 45% Loosely correlated | -1.19% | ||
| GSK - GILD | 40% Loosely correlated | -2.84% | ||
| AZN - GILD | 39% Loosely correlated | -1.66% | ||
| BIIB - GILD | 38% Loosely correlated | -1.05% | ||
More | ||||